MedDay's MD1003 study fails to reach primary endpoint

A second placebo-controlled study of MD1003 in the treatment of progressive multiple sclerosis has failed to reach its primary endpoint, it has been revealed.

The MS-ON study, conducted by Paris, France-based biotech firm MedDay, was designed to investigate the superiority of MD1003, a highly-concentrated pharmaceutical-grade biotin administered at a dose of 300mg per day, over placebo in the visual improvement of patients suffering from chronic visual loss resulting from optic neuritis (MS-ON).

Patients who received MD1003 tended to improve slightly more than patients who received the placebo but the difference did not reach statistical significance.